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Signal transducer and activator of transcription 3 (STAT3) protects the heart from acute
ischemic stress. However, the importance of STAT3 to the heart in chronic stress,
such as hypertension, is not known. To study this, we used cardiomyocyte-targeted
STAT3 knockout (KO) mice and Angiotensin II (ANG II) infusion by osmotic minipumps.
After 4 weeks, ANG II induced similar cardiac hypertrophy in wild type (WT) and
cardiac Cre-expressing control (CTRL) mice with no impairment of cardiac function. In
contrast, STAT3 KO mice exhibited reduced contractile function but similar hypertrophy
to CTRL mice. Ejection fraction and fractional shortening decreased by 22.5 and 27.3%,
respectively. Since STAT3 has direct protective effects on mitochondrial function, we
examined rates of glucose and oleate oxidation by isolated perfused hearts using a
Langendorff system. Hearts of ANG II-treated STAT3 KO and CTRL mice had similar
rates of oleate oxidation as saline-infused WT mice. Rates of glucose oxidation were
similar between hearts of WT plus saline and CTRL plus ANG II mice; however, glucose
oxidation was increased by 66% in hearts of ANG II-treated STAT3 KO mice. The ratio of
maximal ATP yield from glucose to fatty acid oxidation was 21.1 ± 3.1 in hearts of ANG
II-treated STAT3 KO mice vs. 12.6 ± 2.2 in hearts of ANG II-treated CTRL mice. Lactate
production was also elevated in hearts of ANG II-treated STAT3 KO mice by 162%
compared to ANG II-treated CTRL mice. Our findings indicate that STAT3 is important
for maintaining contractile function and metabolic homeostasis in the hypertensive heart,
and STAT3 deficiency promotes a switch toward glucose utilization.
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INTRODUCTION
Heart Failure is a leading cause of death in the USA and developed world, and while survival
after diagnosis has improved over time, the death rate remains high with ∼50% mortality within
5 years of diagnosis (Roger et al., 2012). The total estimated annual cost of heart failure is
>30 billion dollars and that figure is expected to more than double over the next decade due
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to an aging population (Heidenreich et al., 2013). Hypertension
is the second most common risk factor for heart failure and
accounts for ∼25% of heart failure cases (Kannel and Cobb,
1992). In the elderly, as many as 68% of heart failure cases are
linked to hypertension and community-based studies indicate
hypertension contributes to heart failure in 60% of patients
(Yamasaki et al., 2003).
Accumulating evidence indicates that preserving
bioenergetics, including maintaining mitochondrial fatty acid
oxidation (FAO), is critical for cardiac function and preventing
both ischemic and non-ischemic heart failure (Abdurrachim
et al., 2015; Kundu et al., 2015). Hypertension-induced cardiac
hypertrophy is associated with a reduction in FAO and increased
reliance on anaerobic glycolysis (Kolwicz et al., 2012). The basis
for the metabolic reprogramming of the hypertrophied and early
stage failing heart is not understood, but seems to involve both
transcriptional and mitochondrial post-transcriptional events
(Lai et al., 2014).
Signal transducer and activator of transcription 3 (STAT3)
was originally identified as a transcription factor and was
subsequently shown to be important in the heart for inducing a
protective gene program associated with delayed preconditioning
of myocardium (Kurdi and Booz, 2007; Zouein et al., 2015).
The importance of STAT3 in protecting the heart from chronic
stresses, such as hypertension, is not known. Additionally, STAT3
is now known to have protective actions that do not involve
gene expression. Two sites of phosphorylation in the C-terminal
transcription activation domain (TAD) of STAT3 constitute
an on-switch for its activation (Zouein et al., 2015). Y705
phosphorylation in canonical signaling leads to gene expression.
S727 phosphorylation enhances gene expression, but also has
novel genomic and non-genomic actions that are independent
of Y705 phosphorylation. We recently reported that mice with a
global S727A mutation in STAT3 that precludes phosphorylation,
devoid of a baseline phenotype, exhibit a loss of cardiac myocytes
and diminished contractile function in response to the chronic
stress of pressure overload due to hypertension (Zouein et al.,
2013). Our findings suggest that STAT3 protects the heart
from the harmful effects of hypertension, but the basis for this
protection is not known.
The non-genomic actions of STAT3 include unexplained
direct protective actions on the mitochondrial electron transport
chain (ETC). STAT3 is present in heart mitochondria and
reduced STAT3 content impairs respiratory function, reduces
activity of complex I, and increases susceptibility of the
mitochondrial permeability transition pore (mPTP) to open,
a harbinger of cell death (Zouein et al., 2015). In this study,
we assessed the importance of cardiac myocyte-specific STAT3
in maintaining the homeostasis of cardiac energy metabolism
during hypertension using mice expressing a STAT3 in the heart
lacking the domain important for both its mitochondrial and
genomic actions.
MATERIALS AND METHODS
Materials
Angiotensin II (ANG II) acetate was from Bachem (Torrance,
CA, USA). Probumin bovine serum albumin fatty acid-free was
from EMD Millipore (Billerica, MA, USA). PerkinElmer was the
source for [9,3-3H]oleate and [U-14C]glucose. Insulin (Humulin
R U-100) was from Eli Lilly and Company (Indianapolis, IN,
USA). The lactate assay kit (MAK064) was from Sigma-Aldrich
(St. Louis, MO, USA).
Animals
The STAT3 floxed mice were originally produced by Takeda
et al. (1998). Briefly, STAT3 KO mice that express a functionally
deficient STAT3 lacking the C-terminus TAD selectively in
cardiac myocytes were generated by crossing STAT3 floxed
(exons 21 and 22) mice with mice expressing Cre recombinase
under the control of the αMHC promoter (Figure 1).
The STAT3 KO mice were homozygous for loxP-flanked
STAT3 alleles and hemizygous for the Cre transgene. Further
validation of the generated STAT3 KO mice is reported in
FIGURE 1 | Diagram showing the excised region of the Signal Transducer and Activator of Transcription 3 (STAT3) gene in the cardiac
myocyte-targeted STAT3 knockout (KO) mice. The two regulatory sites of phosphorylation (Y705 and S727) are highlighted.
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FIGURE 2 | Effect of STAT3 deletion on cardiac function in Angiotensin II (ANG II-treated mice). (A) Ejection fraction (EF) and (B) fractional shortening (FS)
were assessed by echocardiography in control (CTRL) and STAT3 KO mice infused with ANG II and wild type (WT) mice infused with saline. Measurements were
performed on day 0, 14, and 28 and presented as the relative change from day 0. ∗∗∗∗p ≤ 0.0001, n ≥ 11.
the Supplementary Material (Supplementary Figure 1). Age-
matched (2–4 months old) wild type mice and cardiomyocyte-
expressing Cre recombinase mice were used as controls (CTRLs).
Mice were on the C57BL/6 background (αMyHC-Cre; The
Jackson Laboratory, Bar Harbor, ME, USA) and studies were
performed on male mice. Animals were maintained on 8640
Teklad 22/5 rodent diet (Harlan Laboratories, Indianapolis, IN,
USA).
Study Protocol
The study complied with the Guide for the Care and Use
of Laboratory Animals: Eighth Edition (National Academy
of Sciences Institute for Laboratory Animal Research, 2011)
and was approved by the Institutional Animal Care and Use
Committee of UMMC (protocol #1192B). Saline (0.9%) or ANG
II (1000 ng/kg/min) was delivered via Alzet miniosmotic pumps
(Model 1004) implanted subcutaneously for 28 days. Animals
were treated with ibuprofen (4 mg/Kg IP) as analgesic for 1 day
following implantation of pumps.
Echocardiography
Cardiac function was assessed by echocardiography using
a VEVO 770 high resolution in vivo imaging system from
VisualSonics. Echocardiography was performed prior to pump
implantation, at the midway point, and at study completion.
Measurements were made with a 707B RMV scanhead with
a center frequency of 25 MHz and frequency band ranging
from 12.5 to 37.5 MHz. Mice were anesthetized with 1.5%
isoflurane and placed on pre-warmed EKG transducer pad
with heart rate, body temperature, and EKG monitored.
Two-dimensional B-mode parasternal long axis views
were obtained first to visualize aortic and mitral valves.
The transducer was then rotated clockwise 90◦ to obtain
the parasternal short axis view. Ejection fraction (EF) and
fractional shortening (FS) were determined from the M-mode
images.
Fatty Acid and Glucose (Glc) Oxidation
Ex vivo cardiac metabolic analyses were performed as previously
described (Wu et al., 2015). Briefly, mice were anesthetized
with Inactin hydrate (150 mg/kg IP) and anticoagulated with
heparin (40 USP IP). Hearts were rapidly excised and arrested
in ice-cold Krebs–Henseleit buffer. Hearts were mounted on a
Langendorff apparatus and retrogradely perfused at a constant
coronary perfusion pressure of 70 mmHg with non-recirculating
Krebs–Henseleit buffer containing Glc (5.5 mmol/L), sodium
oleate (0.4 mmol/L) bound to bovine serum albumin, [9,3-3H]
oleate (0.2 µCi/mL), [U-14C] Glc (0.1 µCi/mL), and insulin
TABLE 1 | Summary of cardiac function at study completion.
Cardiac Function Group Mean ± SEM P
LVEF (%) WT + Saline 57.33 ± 2.63 ns
WT + ANG II 52.22 ± 3.27
CRE+ + Saline 57.26 ± 3.84 ns
CRE+ + ANG II 54.34 ± 2.38
KO + Saline 58.84 ± 4.73 0.01
KO + ANG II 39.40 ± 2.86
LVFS (%) WT + Saline 30.26 ± 1.81 ns
WT + ANG II 27.11 ± 2.01
CRE+ + Saline 30.82 ± 3.23 ns
CRE+ + ANG II 27.57 ± 1.50
KO + Saline 30.75 ± 3.37 0.0067
KO + ANG II 21.22 ± 1.88
LVEF, Left ventricular ejection fraction; LVFS, Left ventricular fractional shortening;
WT, Wild type mouse; CRE+, Cre recombinase positive mouse; KO, STAT3
knockout mouse; ANG II, Angiotensin II.
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FIGURE 3 | Representative echocardiography B-mode and M-mode images. CTRL and STAT3 KO mice were infused with ANG II for 28 days; WT mice were
infused with saline. Compared to WT mice, CTRL and KO mice exhibited increased wall thickness.
FIGURE 4 | Quantification of cardiac hypertrophy detected by echocardiography. Changes in left ventricular anterior wall (LVAW) and posterior wall
(LVPW) at 28 days of treatment are shown in panels (A,B), respectively. ∗∗∗∗p ≤ 0.001, n ≥ 11.
(40 µU/mL). The buffer was equilibrated with 95% O2–5% CO2
and maintained at 37◦C. After stabilization for 30 min, rates
of oleate and Glc oxidation were determined by quantitative
collection of [3H]2O and [14C]O2 from the coronary eﬄuent.
Statistics
Values are reported as mean± SEM for n number of independent
observations. For single comparisons, statistical significance was
determined by a Student’s t-test. For multiple comparisons, one-
way or two-way ANOVA followed by an appropriate post hoc test
was used. Statistical significance was taken as p ≤ 0.05.
RESULTS
Cardiac STAT3 Deletion Impairs
Contractility with Hypertension, but Does
Not Prevent Hypertrophy
Angiotensin II (ANG II)-infusion of mice for 28 days was
used as a model of hypertension-induced cardiac hypertrophy,
which commonly precedes heart failure (Booz, 2007). Cardiac
function was assessed by echocardiography. Contractile function
was maintained by hearts of both WT and Cre+ mice treated
with ANG II as assessed by EF and FS (Supplementary Figure 2).
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FIGURE 5 | ANG II-induced similar cardiac hypertrophy in CTRL and STAT3 KO mice. Mice were infused for 28 days with ANG II (CTRL and STAT3 KO)
or saline (WT). Cardiac hypertrophy was assessed as (A) heart weight to tibia length (HW/TL) ratio or (B) heart weight to body weight ratio (HW/BW).
∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001, n ≥ 11.
FIGURE 6 | Assessment of metabolism in perfused hearts. Mice were treated for 28 days with ANG II (CTRL or STAT3 KO) or saline (WT). Rates of (A)
fatty acid oxidation (FAO) and (B) glucose oxidation (GO) were assessed in hearts mounted on a Langendorff apparatus. ∗p ≤ 0.05, n ≥ 11. gdw, gram dry weight.
Since no difference was observed between WT and Cre+ mice
for subsequent studies the two groups were pooled as CTRLs.
The time course for the effect of ANG II on cardiac function
is shown in Figure 2. Hearts of STAT3 KO mice exhibited a
decline in contractile function that was already in evidence by
day 14 (Figure 2). EF was reduced by 25.7 ± 7.0 % (n = 11,
p = 0.001) and FS by 30.1 ± 8.0 % (n = 11, p = 0.001) at day
28 when compared to CTRLs. Table 1 provides the EF and FS
values at 28 days for all groups and shows that loss of cardiac
STAT3 resulted in reduced EF and FS in response to ANG II
infusion.
Loss of cardiomyocyte STAT3 did not have an effect
on the development of cardiac hypertrophy with ANG II.
Cardiac anatomy evidenced by ultrasounds displayed a similar
hypertrophic morphology for STAT3 KO and CTRL ANG II
treated mice (Figures 3 and 4). ANG II infusion induced similar
hypertrophy of STAT3 KO and CTRL hearts as assessed by an
increase in the heart weight to tibia length (Figure 5A) and the
heart weight to body weight ratio (Figure 5B).
Cardiac STAT3 Deletion Does Not Impair
FAO and Increases Glucose Oxidation
Cardiac FAO was not affected by ANG II infusion in either
CTRL or STAT3 KO mice (Figure 6A). In addition, no
effect of ANG II on rates of Glc oxidation was seen in
hearts of CTRL mice. However, as seen in Figure 6B, rates
of Glc oxidation were enhanced in the hearts of STAT3
KO mice by 66% (n = 16, p = 0.018). Glc oxidation as
a fraction of FAO was significantly increased by ANG II
treatment in STAT3 KO hearts of mice compared to hearts
of CTRL mice (Figure 7A) and the ratio of maximal ATP
yield from Glc oxidation to FAO was increased with ANG
II treatment by 68% in hearts of STAT3 KO mice compared
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FIGURE 7 | Shift toward increased glucose oxidation over fatty acid oxidation in STAT3 KO hearts with ANG II treatment. (A) Relative contribution of GO
to FAO in hearts of CTRL and STAT3 KO mice infused with ANG II or WT mice infused with saline for 28 days. (B) Maximal ATP yield from glucose to fatty acid
oxidation. ∗p ≤ 0.05, n ≥ 11.
to hearts of CTRL mice (Figure 7B). As seen in Figure 8,
lactate production was also elevated in STAT3 KO hearts
with ANG II infusion compared to CTRL hearts treated with
ANG II.
DISCUSSION
Late stage cardiac hypertrophy and heart failure are associated
with impaired mitochondrial FAO and a shift to greater reliance
on Glc metabolism, which is thought to be inadequate for normal
cardiac function (Lai et al., 2014). In our study, we observed
that mitochondrial FAO is maintained for upward of 28 days
with ANG II-induced hypertension and cardiac hypertrophy.
Others previously reported that hearts of ANG II-infused mice
do not show impaired FAO at 7 days (Mori et al., 2013). More
FIGURE 8 | Effect of STAT3 KO on lactate production in hypertrophied
hearts. CTRL and STAT3 KO mice were treated with ANG II for 28 days.
Lactate production was assessed in hearts mounted on a Langendorff
apparatus. ∗p ≤ 0.05, n ≥ 11.
significantly, FAO was not altered in the hearts of STAT3 KO mice
treated with ANG II for 28 days, although these mice exhibited
cardiac dysfunction at 14 days that persisted out to 28 days. Thus,
we conclude that STAT3 is not important in the heart to maintain
normal fatty acid utilization under chronic stress conditions of
ANG II infusion, despite the fact that STAT3 deficiency has been
reported to impair ETC function in the heart, including complex
I and II activities (Wegrzyn et al., 2009).
We observed that Glc oxidation was increased in STAT3
KO mice treated with ANG II. Unexpectedly, FAO was not
altered, which we would have predicted to decrease due to
the Randle cycle (Heather and Clarke, 2011). Increased Glc
oxidation in the face of unaltered FAO is further evidence
that mitochondrial metabolic function is not adversely affected
by STAT3 deletion in the heart under the chronic stress
condition of cardiac hypertrophy. However, STAT3 loss may
have compromised one or more regulatory mechanism associated
with controlling the balance between Glc oxidation and FAO
and precipitated the development of metabolic alterations
associated with pathological remodeling of the heart. Our
observation that hearts of STAT3 KO mice treated with ANG II
produce more lactate than CTRL hearts is further evidence that
glycolytic flux is enhanced in these hearts as well, as increased
workload on the heart eventually leads to increased Glc uptake,
glycogenolysis, glycolytic flux, and pyruvate oxidation (Depre
et al., 1999). Under certain conditions, enhanced glycolysis has
been associated with metabolic acidosis and impaired mechanical
function of the heart (Clanachan, 2006; Hall et al., 2016),
and therefore may have contributed to the impaired cardiac
contractility that we observed in STAT3 KO mice treated with
ANG II.
Our findings of contractile impairment and increased Glc
oxidation in the absence of a decrease in FAO are reminiscent
of results reported by Yan et al. (2009). In their study, increased
Glc uptake and oxidation in the mouse heart overexpressing the
Glc transporter GLUT1 was associated with cardiac dysfunction
in diet-induced obesity in the absence of any change in the
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contribution of FAO to total substrate use. In addition, unlike
WT hearts, these transgenic hearts failed to demonstrate a
decrease in FAO when challenged by increased work load,
suggesting a loss of metabolic flexibility. Moreover, hearts of
transgenic mice fed a high fat diet were unable to sustain the
high contractile performance associated with high workload. The
increase reliance on Glc oxidation in the absence of any change
in FAO was associated with oxidative stress and enhanced p38
activation, both of which have been implicated in contractile
dysfunction.
Our study also reveals that cardiac myocyte expression
of STAT3 is not important for the development of cardiac
hypertrophy in response to ANG II-induced hypertension. No
difference in the extent of cardiac hypertrophy was found
between STAT3 KO and CTRL mice. Genetic deletion of IL-
6 was recently reported to attenuate pressure overload-induced
cardiac hypertrophy (Zhao et al., 2016). IL-6 is a strong
inducer of STAT3 and by inference STAT3 was implicated
in left ventricular hypertrophy and dysfunction in this study.
However, IL-6 activates other signaling pathways that might
contribute to cardiac hypertrophy, including several that affect
calcium handling, a proven protagonist of cardiac myocyte
hypertrophic growth. As discussed elsewhere (Kurdi and Booz,
2007), the conclusion the STAT3 couples to cardiac hypertrophy
is largely based on circumstantial evidence obtained using cells in
culture; definitive evidence that endogenous STAT3 is essential
for physiological or pathological hypertrophy of the heart is
lacking.
Our study has certain limitations. No difference was observed
between WT and Cre+ mice in cardiac function with or
without ANG II infusion. However, we cannot preclude the
possibility that subtle differences were present at a subcellular
level. Nonetheless, STAT3 KO hearts behaved differently from
Cre+ expressing hearts with ANG II infusion, highlighting a
unique role of this transcription factor in the heart under
stress conditions. In addition, we performed our study with
male mice since the degree of hypertension induced by ANG
II is greater in male mice. Future studies will need to assess
whether STAT3 has sex-specific effects in the heart. Plus, loss of
STAT3 may have removed an ANG II-activated cardioprotective
mechanism, rather than eliminated a broad based endogenous
protective mechanism (Altara et al., 2016). Whether STAT3
protects the heart in other models of cardiac hypertrophy will
need to be assessed. Finally, ANG II is known to have both
blood pressure-dependent and -independent effects in the heart.
Our study was not designed to discriminate between these two
effects.
CONCLUSION
Our results clearly show that mitochondrial function as assessed
by both fatty acid and Glc oxidation is not adversely affected
by STAT3 deletion following 4 weeks treatment with ANG II.
Moreover, we report for the first time that cardiac myocyte-
specific STAT3 is not important for hypertrophic growth in
response to increased blood pressure. Therefore, our findings
suggest that the direct non-genomic actions of STAT3 at the level
of the mitochondria do not play a role in the development of heart
failure in response to increased cardiac hypertrophy.
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